Think tuberculosis-but is thinking enough? by Keller, Peter M & Furrer, Hansjakob
Comment
www.thelancet.com/infection   Published online March 13, 2020   https://doi.org/10.1016/S1473-3099(20)30138-9 1
In The Lancet Infectious Diseases, David Barr and 
colleagues1 report on Mycobacterium tuberculosis blood­
stream infection (BSI) in seriously ill HIV­infected adults. 
In a systematic review and meta­analysis of individual 
patient data from 20 published and three unpublished 
studies and datasets, Barr and colleagues found a higher 
prevalence of M tuberculosis­positive blood cultures 
in critically ill HIV­infected patients with tuberculosis 
than previously reported in a review in a less selected 
population2 (45% vs 15·5%) and a higher risk of 
mortality within 30 days in those with M tuberculosis 
BSI than in those without (adjusted hazard ratio 2·48, 
95% CI 2·05–3·08). Furthermore, they found that 
delaying tuberculosis treatment for more than 4 days 
in critically ill patients with M tuberculosis BSI was 
associated with increased early mortality compared with 
no delay (odds ratio 3·2, 95% CI 1·2–8·8).
The conclusions of the study seem straightforward: 
as with any bacterial BSI we should not delay 
antimicrobial treatment for HIV­infected patients 
with M tuberculosis BSI. However, how do we identify 
these patients? Even in settings where blood cultures 
for tuberculosis can be done, the results will only be 
available after more than 10 days, too late to define 
early treatment strategies based on microbiology 
results. A tuberculosis­positive blood culture is a 
marker of disseminated tuberculosis but by no means 
a perfect one. As with bacterial blood cultures, the 
likelihood of finding positive results depends on 
the amount of blood that is cultured, and with one 
or even two negative cultures we cannot exclude 
disseminated tuberculosis.3 Disseminated tuberculosis 
is associated with HIV­induced immunosuppression, 
especially in patients on antiretroviral therapy and with 
low CD4 cell counts.4 Although tuberculosis usually 
progresses slowly because of the long generation 
time of the bacterium, disseminated tuberculosis 
might also present rapidly, akin to sepsis (so­called 
Landouzy sepsis, named after the French physician 
Louis Théophile Josef Landouzy, 1845–1917). This 
manifestation is more often encountered in regions 
with high HIV and tuberculosis prevalence. Since HIV­
infected patients with disseminated tuberculosis rarely 
have cavitary lung disease with high mycobacterial 
load in sputum, rapid sputum­based diagnostic tests, 
such as microscopy or PCR­based Xpert MTB/RIF, might 
be negative, as was the case for 28% of the patients 
with M tuberculosis BSI in the analysis (appendix 
p 14). By contrast, tests for urinary lipoarabinomannan 
(LAM) are more likely to be positive in disseminated 
tuberculosis than in pulmonary tuberculosis, and 
the diagnostic yield of urine LAM for patients with 
M tuberculosis BSI in the study was 52% (95% CI 
35–69). The authors estimate that the combined 
diagnostic yield of rapid sputum diagnostics and 
urinary LAM for prediction of M tuberculosis BSI is 82% 
(71–90%; appendix p 14). Therefore, in about one in 
six (100/18) patients with tuberculosis BSI we would 
have no positive rapid laboratory test pointing towards 
tuberculosis.
Coming back to the clinical situation, we are 
confronted with a seriously ill HIV­infected patient 
with danger signs, such as increased respiration rate, 
high temperature, elevated heart rate, or inability to 
walk. According to WHO guidance,5 we would start with 
empirical antibacterial therapy and look for tuberculosis 
by Xpert MTB/RIF. If Xpert is negative and the patient 
shows no clinical improvement after 3–5 days of 
parenteral antibiotics, WHO recommends starting 
tuberculosis therapy. However, taking the data from 
Barr and colleagues’ study1 into account, is delaying 
tuberculosis treatment the right thing to do?
In patients at risk of disseminated tuberculosis 
with danger signs, we would, on the basis of Barr and 
colleagues’ findings, add a urinary LAM test to Xpert 
and start tuberculosis treatment if one of these tests 
is positive. However, even with these two rapid tests 
we would probably miss about 18% of patients with 
disseminated tuberculosis and put them at higher 
mortality risk if we defer tuberculosis treatment for 
4 days or more. Does that mean we should treat every 
patient with anti­tuberculosis therapy, in addition 
to empirical antibiotics, irrespective of tuberculosis test 
results, from the beginning?
This decision depends on the prevalence of 
tuberculosis in the population we care for. If the risk 
of tuberculosis is near to zero (eg, in regions with 
low tuberculosis prevalence), the negative aspects 
of treating all patients for tuberculosis, including 
costs, side­effects, and drug interactions, outweigh 
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the potential benefits. However, in settings where 
tuberculosis prevalence is high (eg, in sub­Saharan 
Africa and south and southeast Asia), not delaying 
tuberculosis treatment might be recommended even in 
patients with negative rapid tuberculosis test results.
Although such an approach is feasible in regions 
with low prevalence of multidrug­resistant (MDR) 
tuberculosis, how would we start tuberculosis treat­
ment in settings where prevalence of MDR tuberculosis 
is high. In case of a positive Xpert MTB/RIF, we have 
decision guidelines6 to start tuberculosis treatment 
according to the result of the rifampicin test. But 
what would we do in the case of positive urinary LAM 
or negative rapid tests but a high pre­test likelihood 
of tuberculosis? Would we start an MDR tuberculosis 
treatment regimen with even more side­effects and 
costs, or would we start conventional tuberculosis 
treatment? Finally, should we give a full course of 
tuberculosis treatment to all critically ill patients in 
settings of high tuberculosis prevalence with negative 
rapid tuberculosis tests, thus confirming a diagnosis of 
tuberculosis if the patient’s health improves in a few 
days?
These questions must be answered before we 
can design algorithms for diagnosis and treatment 
of suspected M tuberculosis BSI for integration into 
public health strategies. Therefore, let us think, 
discuss, and design implementation trials for the sake 
of our patients’ survival.
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